Gilead Plans to Make 2 Million Remdesivir Doses This Year (2)

July 30, 2020, 10:20 PM

Gilead Sciences Inc. said Thursday it expects to make more than 2 million doses of Covid-19 treatment remdesivir by year-end.

In May, the antiviral therapy received an emergency-use authorization to treat Covid-19, the disease caused by the novel coronavirus, after a major trial found it sped recovery by about four days in hospitalized patients. It is already being used in clinical practice.

In its second-quarter earnings report, Gilead raised its outlook for the year, pointing in part to early success of remdesivir. It now expects earnings per share of $6.25 to $7.65, up from its earlier projections of $6.05 to...

To read the full article log in.

Learn more about a Bloomberg Law subscription.